Switzerland· 35856002
Bleomycin Baxter, Pulver zur Herstellung einer Injektions-/Infusionslösung
A bleomycin product, registered in Switzerland by Baxter AG and dispensed under Swissmedic category A. The same ATC class is registered in 15 of our 19 countries.
Checked against the register on
Informational only — not a medical device.
Where it is registered
Bleomycin is registered in 15 of 19 countries.
Countries holding a registration under ATC L01DC01 (bleomycin), each read from that country’s own register.
- This record: Switzerland
- 9 of them publish a price we can compare per daily dose
Bleomycin · ATC L01DC01
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
- Manufacturer
- Baxter AG
- Country
- Switzerland (CH)
- ATC code
- L01DC01
- ATC class
- Bleomycin
- Defined daily dose
- 3 mg, P
- Swissmedic category
- A
- Reimbursed
- No
- Last checked
- June 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
212 interactions on record for bleomycin.
Graded by severity as the source publishes them — 33 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Bleomycin · interactions on record
212 records
- 33 severe
- 105 moderate
- 15 minor
- 59 info
Most severe, free to view
- CladribineL01BB04severe
- Brentuximab vedotinL01FX05severe
- Brentuximab vedotinL01XC12severe
- Talimogene laherparepvecL01XL02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L01DC01
Bleomycin, as other registers publish it.
- GermanyBleo-CellStadapharm Gmbh
- GermanyBleo-CellStadapharm Gmbh
- United KingdomBleo-Kyowa 15,000unit powder for solution for injection vialsKyowa Kirin Ltd
- GermanyBleomedacMedac Gesellschaft Für Klinische Spezialpräparate Mbh (Wedel)
- PolandBleomedacmedac Gesellschaft fuer klinische Spezialpraeparate mbH
- GermanyBleomedacMedac Gesellschaft Für Klinische Spezialpräparate Mbh (Wedel)
- CzechiaBLEOMEDACMedac Gesellschaft für klinische Spezialpräparate m.b.H., Wedel
- CzechiaBLEOMEDACMedac Gesellschaft für klinische Spezialpräparate m.b.H., Wedel
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e475350b-1c43-4f8b-8b91-27d189e3b138 GET /v1/drugs/e475350b-1c43-4f8b-8b91-27d189e3b138?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "swissmedic_auth",
"heilmittelcode": "Synthetika"
}See everything about bleomycin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.